Advertisement

Der Hautarzt

, Volume 66, Issue 6, pp 413–422 | Cite as

Hidradenitis suppurativa/Acne inversa

Ein Update
  • J. Kirschke
  • S. Hessam
  • F.G. BecharaEmail author
Leitthema

Zusammenfassung

Hidradenitis suppurativa/Acne inversa (HS/AI) ist eine chronische, inflammatorische Hauterkrankung, die sich durch schmerzhafte Knoten, Abszesse, Fisteln und Vernarbungen auszeichnet und zu deutlichen funktionellen sowie psychologischen Beeinträchtigungen bei den betroffenen Patienten führen kann. Es vergehen oft Jahre, bis die richtige Diagnose gestellt wird. Die Behandlung der HS/AI stellt weiterhin eine Herausforderung dar. Konservative Therapien können in initialen Stadien der Erkrankung zu einer Besserung, nicht aber Heilung der Erkrankung führen. Bei fortgeschrittenen Stadien bleibt die radikale Exzision weiterhin die Therapie der Wahl.

Schlüsselwörter

Inflammatorische Erkrankung Verlauf Therapie Diagnose Exzision 

Hidradenitis suppurativa/acne inversa

An update

Abstract

Hidradenitis suppurativa/acne inversa (HS/AI) is a chronic inflammatory disease characterized by painful nodules, abscesses, fistulas, sinus tracts and scarring, which may lead to severe functional and psychological impairment. Patients often suffer for many years before the right diagnosis is finally made. HS/AI is still a therapeutic challenge. Conservative therapies play a role in mild stages of the disease; however they do not result in healing. Therapy of choice associated with the lowest recurrence rate is a radical wide excision of involved skin.

Keywords

Inflammatory disease Treatment outcome Therapy Diagnosis Excision 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

J. Kirschke, S. Hessam und F.G. Bechara geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Alle Patienten, die über Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts zu identifizieren sind, haben hierzu ihre schriftliche Einwilligung gegeben. Im Falle von nicht mündigen Patienten liegt die Einwilligung eines Erziehungsberechtigten oder des gesetzlich bestellten Betreuers vor.

Literatur

  1. 1.
    Adams DR, Yankura JA, Fogelberg AC et al (2010) Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol 146:501–504PubMedGoogle Scholar
  2. 2.
    Al-Ali FMS, Ratnamala U, Mehta TY et al (2010) Hidradenitis suppurativa (or Acne inversa) with autosomal dominant inheritance is not linked to chromosome 1p21.1–1q25.3 region. Exp Dermatol 19:851–853PubMedCrossRefGoogle Scholar
  3. 3.
    Alikhan A, Lynch PJ, Eisen DB (2009) Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 60:539–561. (quiz 562–533)Google Scholar
  4. 4.
    Amano M, Grant A, Kerdel FA (2010) A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa. Int J Dermatol 49:950–955PubMedCrossRefGoogle Scholar
  5. 5.
    Arenbergerova M, Gkalpakiotis S, Arenberger P (2010) Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy. Int J Dermatol 49:1445–1449PubMedCrossRefGoogle Scholar
  6. 6.
    Barth JH, Layton AM, Cunliffe WJ (1996) Endocrine factors in pre- and postmenopausal women with hidradenitis suppurativa. Br J Dermatol 134:1057–1059PubMedCrossRefGoogle Scholar
  7. 7.
    Bechara FG, Hartschuh W (2010) Acne inversa. Hautarzt 61:39–46PubMedCrossRefGoogle Scholar
  8. 8.
    Bechara FG, Sand M, Skrygan M et al (2012) Acne inversa: evaluating antimicrobial peptides and proteins. Ann Dermatol 24:393–397PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Bendahan J, Paran H, Kolman S et al (1992) The possible role of Chlamydia trachomatis in perineal suppurative hidradenitis. Eur J Surg 158:213–215PubMedGoogle Scholar
  10. 10.
    Blok JL, Van Hattem S, Jonkman MF et al (2013) Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review. Br J Dermatol 168:243–252PubMedCrossRefGoogle Scholar
  11. 11.
    Boer J, Nazary M (2011) Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer? Br J Dermatol 164:170–175PubMedCrossRefGoogle Scholar
  12. 12.
    Brocard A, Knol A-C, Khammari A et al (2007) Hidradenitis suppurativa and zinc: a new therapeutic approach. A pilot study. Dermatology 214:325–327PubMedCrossRefGoogle Scholar
  13. 13.
    Canoui-Poitrine F, Revuz JE, Wolkenstein P et al (2009) Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 61:51–57PubMedCrossRefGoogle Scholar
  14. 14.
    Chen YE, Gerstle T, Verma K et al (2014) Management of hidradenitis suppurativa wounds with an internal vacuum-assisted closure device. Plast Reconstr Surg 133:370e-377ePubMedCrossRefGoogle Scholar
  15. 15.
    Constantinou C, Widom K, Desantis J et al (2008) Hidradenitis suppurativa complicated by squamous cell carcinoma. Am Surg 74:1177–1181PubMedGoogle Scholar
  16. 16.
    Cosmatos I, Matcho A, Weinstein R et al (2013) Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol 68:412–419PubMedCrossRefGoogle Scholar
  17. 17.
    Danby FW, Jemec GBE, Marsch WC et al (2013) Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support. Br J Dermatol 168:1034–1039PubMedCrossRefGoogle Scholar
  18. 18.
    Deckers IE, Van Der Zee HH, Boer J et al (2015) Correlation of early-onset hidradenitis suppurativa with stronger genetic susceptibility and more widespread involvement. J Am Acad Dermatol 72:485–488PubMedCrossRefGoogle Scholar
  19. 19.
    Downs A (2004) Smoothbeam laser treatment may help improve hidradenitis suppurativa but not Hailey-Hailey disease. J Cosmet Laser Ther 6:163–164PubMedCrossRefGoogle Scholar
  20. 20.
    Dreno B, Khammari A, Brocard A et al (2012) Hidradenitis suppurativa: the role of deficient cutaneous innate immunity. Arch Dermatol 148:182–186PubMedCrossRefGoogle Scholar
  21. 21.
    Durmaz R, Tekerekoǧlu MS, Kalcioǧlu T et al (2001) Nasal carriage of methicillin-resistant Staphylococcus aureus among smokers and cigarette factory workers. New Microbiol 24:143–147PubMedGoogle Scholar
  22. 22.
    Emelianov VU, Bechara FG, Gläser R et al (2012) Immunohistological pointers to a possible role for excessive cathelicidin (LL-37) expression by apocrine sweat glands in the pathogenesis of hidradenitis suppurativa/acne inversa. Br J Dermatol 166:1023–1034PubMedCrossRefGoogle Scholar
  23. 23.
    Estrach S, Cordes R, Hozumi K et al (2008) Role of the Notch ligand Delta1 in embryonic and adult mouse epidermis. J Invest Dermatol 128:825–832PubMedCrossRefGoogle Scholar
  24. 24.
    Fain JN (2006) Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 74:443–477PubMedCrossRefGoogle Scholar
  25. 25.
    Fitzsimmons JS, Guilbert PR, Fitzsimmons EM (1985) Evidence of genetic factors in hidradenitis suppurativa. Br J Dermatol 113:1–8PubMedCrossRefGoogle Scholar
  26. 26.
    Gao M, Wang P-G, Cui Y et al (2006) Inversa acne (hidradenitis suppurativa): a case report and identification of the locus at chromosome 1p21.1–1q25.3. J Invest Dermatol 126:1302–1306PubMedCrossRefGoogle Scholar
  27. 27.
    Gener G, Canoui-Poitrine F, Revuz JE et al (2009) Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology 219:148–154PubMedCrossRefGoogle Scholar
  28. 28.
    Giamarellos-Bourboulis EJ, Antonopoulou A, Petropoulou C et al (2007) Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. Br J Dermatol 156:51–56PubMedCrossRefGoogle Scholar
  29. 29.
    Girouard SD, Falk RH, Rennke HG et al (2012) Hidradenitis suppurativa resulting in systemic amyloid A amyloidosis: a case report and review of the literature. Dermatol Online J 18:2PubMedGoogle Scholar
  30. 30.
    Grant A, Gonzalez T, Montgomery MO et al (2010) Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 62:205–217PubMedCrossRefGoogle Scholar
  31. 31.
    Gulliver WP, Jemec GBE, Baker KA (2012) Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol 26:911–914PubMedCrossRefGoogle Scholar
  32. 32.
    Hana A, Booken D, Henrich C et al (2007) Functional significance of non-neuronal acetylcholine in skin epithelia. Life Sci 80:2214–2220PubMedCrossRefGoogle Scholar
  33. 33.
    Harrison BJ, Mudge M, Hughes LE (1987) Recurrence after surgical treatment of hidradenitis suppurativa. Br Med J (Clin Res Ed) 294:487–489CrossRefGoogle Scholar
  34. 34.
    Hazen PG, Hazen BP (2010) Hidradenitis suppurativa: successful treatment using carbon dioxide laser excision and marsupialization. Dermatol Surg 36:208–213PubMedCrossRefGoogle Scholar
  35. 35.
    Hessam S, Sand M, Georgas D et al (2013) Laserepilation bei Hidradenitis suppurativa/Acne inversa und Pilonidalsinus. Aktuelle Derm 39:268–277CrossRefGoogle Scholar
  36. 36.
    Highton L, Chan W-Y, Khwaja N et al (2011) Treatment of hidradenitis suppurativa with intense pulsed light: a prospective study. Plast Reconstr Surg 128:459–465PubMedCrossRefGoogle Scholar
  37. 37.
    Hurley H (1996) Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus. Surgical approach. In: Roenigk R, Roenigk H (Hrsg) Roenigk & Roenigk’s dermatologic surgery: principles and practice, 2. Aufl. Marcel Dekker, New york, S 623–664Google Scholar
  38. 38.
    Jahns AC, Killasli H, Nosek D et al (2014) Microbiology of hidradenitis suppurativa (acne inversa): a histological study of 27 patients. APMIS 122:804–809PubMedCrossRefGoogle Scholar
  39. 39.
    Jain V, Jain A (2012) Use of lasers for the management of refractory cases of hidradenitis suppurativa and pilonidal sinus. J Cutan Aesthet Surg 5:190–192PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Jemec GB (2003) Hidradenitis suppurativa. J Cutan Med Surg 7:47–56PubMedCrossRefGoogle Scholar
  41. 41.
    Jemec GBE (2012) Clinical practice. Hidradenitis suppurativa. N Engl J Med 366:158–164PubMedCrossRefGoogle Scholar
  42. 42.
    Jemec GB, Gottlieb A, Forman S (2014) Efficacy and Safety of Adalimumab in patients with moderate to severe hidradenitis suppurativa: Results from PIONEER II, a Phase 3, randomized, placebo-controlled trial. In: 23rd congress of the EADV, Amsterdam 2014. Abstract FC08.2Google Scholar
  43. 43.
    Jemec GB, Gniadecka M (1997) Sebum excretion in hidradenitis suppurativa. Dermatology 194:325–328PubMedCrossRefGoogle Scholar
  44. 44.
    Jemec GB, Wendelboe P (1998) Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol 39:971–974PubMedCrossRefGoogle Scholar
  45. 45.
    Jemec GB, Heidenheim M, Nielsen NH (1996) The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 35:191–194PubMedCrossRefGoogle Scholar
  46. 46.
    Jeong SH, Park JH, Kim JN et al (2010) Up-regulation of TNF-alpha secretion by cigarette smoke is mediated by Egr-1 in HaCaT human keratinocytes. Exp Dermatol 19:e206–212PubMedCrossRefGoogle Scholar
  47. 47.
    Join-Lambert O, Coignard H, Jais J-P et al (2011) Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa. Dermatology 222:49–58PubMedCrossRefGoogle Scholar
  48. 48.
    Joseph MA, Jayaseelan E, Ganapathi B et al (2005) Hidradenitis suppurativa treated with finasteride. J Dermatolog Treat 16:75–78PubMedCrossRefGoogle Scholar
  49. 49.
    Kathju S, Lasko LA, Stoodley P (2012) Considering hidradenitis suppurativa as a bacterial biofilm disease. FEMS Immunol Med Microbiol 65:385–389PubMedCrossRefGoogle Scholar
  50. 50.
    Kimball AB, Kerdel F, Adams D et al (2012) Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med 157:846–855PubMedCrossRefGoogle Scholar
  51. 51.
    Kintz P, Henrich A, Cirimele V et al (1998) Nicotine monitoring in sweat with a sweat patch. J Chromatogr B Biomed Sci Appl 705:357–361PubMedCrossRefGoogle Scholar
  52. 52.
    Konety BR, Cooper T, Flood HD et al (1996) Scrotal elephantiasis associated with hidradenitis suppurativa. Plast Reconstr Surg 97:1243–1245PubMedCrossRefGoogle Scholar
  53. 53.
    König A, Lehmann C, Rompel R et al (1999) Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology 198:261–264PubMedCrossRefGoogle Scholar
  54. 54.
    Kraft JN, Searles GE (2007) Hidradenitis suppurativa in 64 female patients: retrospective study comparing oral antibiotics and antiandrogen therapy. J Cutan Med Surg 11:125–131PubMedCrossRefGoogle Scholar
  55. 55.
    Kurek A, Johanne Peters EM, Sabat R et al (2013) Depression is a frequent co-morbidity in patients with acne inversa. J Dtsch Dermatol Ges 11:743–749, 743–750PubMedGoogle Scholar
  56. 56.
    Kurzen H, Wessler I, Kirkpatrick CJ et al (2007) The non-neuronal cholinergic system of human skin. Horm Metab Res 39:125–135PubMedCrossRefGoogle Scholar
  57. 57.
    Kurzen H, Kurokawa I, Jemec GBE et al (2008) What causes hidradenitis suppurativa? Exp Dermatol 17:455–456 (discussion 457–472)PubMedCrossRefGoogle Scholar
  58. 58.
    Lapins J, Jarstrand C, Emtestam L (1999) Coagulase-negative staphylococci are the most common bacteria found in cultures from the deep portions of hidradenitis suppurativa lesions, as obtained by carbon dioxide laser surgery. Br J Dermatol 140:90–95PubMedCrossRefGoogle Scholar
  59. 59.
    Lefort K, Mandinova A, Ostano P et al (2007) Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKα kinases. Genes Dev 21:562–577PubMedCentralPubMedCrossRefGoogle Scholar
  60. 60.
    Leslie KS, Tripathi SV, Nguyen TV et al (2014) An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. J Am Acad Dermatol 70:243–251PubMedCrossRefGoogle Scholar
  61. 61.
    Li T, Wen H, Brayton C et al (2007) Epidermal growth factor receptor and notch pathways participate in the tumor suppressor function of gamma-secretase. J Biol Chem 282:32264–32273PubMedCrossRefGoogle Scholar
  62. 62.
    Lowell S, Jones P, Le Roux I et al (2000) Stimulation of human epidermal differentiation by Delta-Notch signalling at the boundaries of stem-cell clusters. Curr Biol 10:491–500PubMedCrossRefGoogle Scholar
  63. 63.
    Lunniss PJ, Jenkins PJ, Besser GM et al (1995) Gender differences in incidence of idiopathic fistula-in-ano are not explained by circulating sex hormones. Int J Colorectal Dis 10:25–28PubMedCrossRefGoogle Scholar
  64. 64.
    Maclean GM, Coleman DJ (2007) Three fatal cases of squamous cell carcinoma arising in chronic perineal hidradenitis suppurativa. Ann R Coll Surg Engl 89:709–712PubMedCentralPubMedCrossRefGoogle Scholar
  65. 65.
    Martin-Ezquerra G, Masferrer E, Masferrer-Niubò M et al (2015) Use of biological treatments in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 29:56–60PubMedCrossRefGoogle Scholar
  66. 66.
    Matusiak L, Bieniek A, Szepietowski JC (2009) Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm Venereol 89:601–603PubMedCrossRefGoogle Scholar
  67. 67.
    Matusiak L, Bieniek A, Szepietowski JC (2014) Bacteriology of Hidradenitis suppurativa – which antibiotics are the treatment of choice? Acta Derm Venereol 94:699–702PubMedCrossRefGoogle Scholar
  68. 68.
    Melnik BC, Plewig G (2013) Impaired Notch signalling: the unifying mechanism explaining the pathogenesis of hidradenitis suppurativa (acne inversa). Br J Dermatol 168:876–878PubMedCrossRefGoogle Scholar
  69. 69.
    Mendonça CO, Griffiths CEM (2006) Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol 154:977–978PubMedCrossRefGoogle Scholar
  70. 70.
    Miller I, Lynggaard CD, Lophaven S et al (2011) A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol 165:391–398PubMedCrossRefGoogle Scholar
  71. 71.
    Mortaz E, Adcock IM, Ito K et al (2010) Cigarette smoke induces CXCL8 production by human neutrophils via activation of TLR9 receptor. Eur Respir J 36:1143–1154PubMedCrossRefGoogle Scholar
  72. 72.
    Mortimer PS, Lunniss PJ (2000) Hidradenitis suppurativa. J R Soc Med 93:420–422PubMedCentralPubMedGoogle Scholar
  73. 73.
    Mortimer PS, Dawber RP, Gales MA et al (1986) A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol 115:263–268PubMedCrossRefGoogle Scholar
  74. 74.
    Mühlstädt M, Bechara FG, Kunte C (2013) Acne inversa (hidradenitis suppurativa). Erkennen – Verstehen – Therapieren. Hautarzt 64:55–61 (quiz 62)PubMedCrossRefGoogle Scholar
  75. 75.
    Ogawa R (2010) The most current algorithms for the treatment and prevention of hypertrophic scars and keloids. Plast Reconstr Surg 125:557–568PubMedCrossRefGoogle Scholar
  76. 76.
    Ouchi N, Parker JL, Lugus JJ et al (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11:85–97PubMedCentralPubMedCrossRefGoogle Scholar
  77. 77.
    Pan Y, Lin MH, Tian X et al (2004) gamma-secretase functions through Notch signaling to maintain skin appendages but is not required for their patterning or initial morphogenesis. Dev Cell 7:731–743PubMedCrossRefGoogle Scholar
  78. 78.
    Paradela S, Rodriguez-Lojo R, Fernandez-Torres R et al (2012) Long-term efficacy of infliximab in hidradenitis suppurativa. J Dermatolog Treat 23:278–283PubMedCrossRefGoogle Scholar
  79. 79.
    Pavia CS, Pierre A, Nowakowski J (2000) Antimicrobial activity of nicotine against a spectrum of bacterial and fungal pathogens. J Med Microbiol 49:675–676PubMedCrossRefGoogle Scholar
  80. 80.
    Pink AE, Simpson MA, Desai N et al (2012) Mutations in the γ-Secretase Genes NCSTN, PSENEN, and PSEN1 Underlie Rare Forms of Hidradenitis Suppurativa (Acne Inversa). J Invest Dermatol 132:2459–2461PubMedCrossRefGoogle Scholar
  81. 81.
    Pink AE, Simpson MA, Desai N et al (2013) γ-Secretase mutations in hidradenitis suppurativa: new insights into disease pathogenesis. J Invest Dermatol 133:601–607PubMedCrossRefGoogle Scholar
  82. 82.
    Plewig G, Steger M (1989) Acne inversa (alias acne triad, acne tetrad or hidradenitis suppurativa). In: Marks R, Plewig G (Hrsg) Acne and related disorders. Martin Dunitz, London, S 345–357Google Scholar
  83. 83.
    Poli F, Wolkenstein P, Revuz J (2010) Back and face involvement in hidradenitis suppurativa. Dermatology 221:137–141PubMedCrossRefGoogle Scholar
  84. 84.
    Prasad AS (2008) Clinical, immunological, anti-inflammatory and antioxidant roles of zinc. Exp Gerontol 43:370–377PubMedCrossRefGoogle Scholar
  85. 85.
    Proweller A, Tu L, Lepore JJ et al (2006) Impaired notch signaling promotes De novo squamous cell carcinoma formation. Cancer Res 66:7438–7444PubMedCrossRefGoogle Scholar
  86. 86.
    Rambhatla PV, Lim HW, Hamzavi I (2012) A systematic review of treatments for hidradenitis suppurativa. Arch Dermatol 148:439–446PubMedCrossRefGoogle Scholar
  87. 87.
    Revuz J (2009) Hidradenitis suppurativa. J Eur Acad Dermatol Venereol 23:985–998PubMedCrossRefGoogle Scholar
  88. 88.
    Revuz JE, Canoui-Poitrine F, Wolkenstein P et al (2008) Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 59:596–601PubMedCrossRefGoogle Scholar
  89. 89.
    Sabat R, Chanwangpong A, Schneider-Burrus S et al (2012) Increased prevalence of metabolic syndrome in patients with Acne inversa. PLoS ONE 7:e31810PubMedCentralPubMedCrossRefGoogle Scholar
  90. 90.
    Sartorius K, Lapins J, Emtestam L et al (2003) Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol 149:211–213PubMedCrossRefGoogle Scholar
  91. 91.
    Sartorius K, Emtestam L, Jemec GBE et al (2009) Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 161:831–839PubMedCrossRefGoogle Scholar
  92. 92.
    Sawers RS, Randall VA, Ebling FJ (1986) Control of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy. Br J Dermatol 115:269–274PubMedCrossRefGoogle Scholar
  93. 93.
    Scheinfeld N (2014) Hidradenitis suppurativa: A practical review of possible medical treatments based on over 350 hidradenitis patients. Dermatol Online J. 2014 Mar 17;20(3). pii: doj_21764Google Scholar
  94. 94.
    Scheinfeld N (2014) A case of a patient with stage III familial hidradenitis suppurativa treated with 3 courses of infliximab and died of metastatic squamous cell carcinoma. Dermatol Online J 20Google Scholar
  95. 95.
    Schlapbach C, Hänni T, Yawalkar N et al (2011) Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol 65:790–798PubMedCrossRefGoogle Scholar
  96. 96.
    Sehgal VN, Verma P, Sawant S et al (2011) Contemporary surgical treatment of hidradenitis suppurativa (HS) with a focus on the use of the diode hair laser in a case. J Cosmet Laser Ther 13:180–190PubMedCrossRefGoogle Scholar
  97. 97.
    Sharon VR, Garcia MS, Bagheri S et al (2012) Management of recalcitrant hidradenitis suppurativa with ustekinumab. Acta Derm Venereol 92:320–321PubMedCrossRefGoogle Scholar
  98. 98.
    Shavit E, Dreiher J, Freud T et al (2015) Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 29:371–376PubMedCrossRefGoogle Scholar
  99. 99.
    Slade DEM, Powell BW, Mortimer PS (2003) Hidradenitis suppurativa: pathogenesis and management. Br J Plast Surg 56:451–461PubMedCrossRefGoogle Scholar
  100. 100.
    Sotiriou E, Goussi C, Lallas A et al (2012) A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa. J Drugs Dermatol 11:s15–20PubMedGoogle Scholar
  101. 101.
    Tierney E, Mahmoud BH, Hexsel C et al (2009) Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminium garnet laser. Dermatol Surg 35:1188–1198PubMedCrossRefGoogle Scholar
  102. 102.
    Torii K, Saito C, Furuhashi T et al (2011) Tobacco smoke is related to Th17 generation with clinical implications for psoriasis patients. Exp Dermatol 20:371–373PubMedCrossRefGoogle Scholar
  103. 103.
    Ulrich A, Hildebrandt U, Ulrich J (2014) Acne inversa: Einfluss assoziierter Faktoren auf den Schweregrad und das operative Ergebnis. Hautarzt 65:623–627PubMedCrossRefGoogle Scholar
  104. 104.
    Van Der Zee HH, Prens EP (2013) Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report. Dermatology 226:97–100PubMedCrossRefGoogle Scholar
  105. 105.
    Van Der Zee HH, Boer J, Prens EP et al (2009) The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology 219:143–147PubMedCrossRefGoogle Scholar
  106. 106.
    Van Der Zee HH, Prens EP, Boer J (2010) Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. J Am Acad Dermatol 63:475–480PubMedCrossRefGoogle Scholar
  107. 107.
    Van Der Zee HH, De Ruiter L, Van Den Broecke DG et al (2011) Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1ß and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1ß. Br J Dermatol 164:1292–1298PubMedCrossRefGoogle Scholar
  108. 108.
    Van Rappard DC, Leenarts MF, Meijerink-Van ’T, Oost L et al (2012) Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa. J Dermatolog Treat 23:284–289PubMedCrossRefGoogle Scholar
  109. 109.
    Vazquez BG, Alikhan A, Weaver AL et al (2013) Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol 133:97–103PubMedCentralPubMedCrossRefGoogle Scholar
  110. 110.
    Verdolini R, Clayton N, Smith A et al (2013) Metformin for the treatment of Hidradenitis suppurativa: a little help along the way. J Eur Acad Dermatol Venereol 27:1101–1108Google Scholar
  111. 111.
    Von Der Werth JM, Williams HC (2000) The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 14:389–392PubMedCrossRefGoogle Scholar
  112. 112.
    Wang B, Yang W, Wen W et al (2010) Gamma-secretase gene mutations in familial acne inversa. Science 330:1065PubMedCrossRefGoogle Scholar
  113. 113.
    Watt FM, Estrach S, Ambler CA (2008) Epidermal Notch signalling: differentiation, cancer and adhesion. Curr Opin Cell Biol 20:171–179PubMedCentralPubMedCrossRefGoogle Scholar
  114. 114.
    Williams ST, Busby RC, Demuth RJ et al (1991) Perineal hidradenitis suppurativa: presentation of two unusual complications and a review. Ann Plast Surg 26:456–462PubMedCrossRefGoogle Scholar
  115. 115.
    Wolkenstein P, Loundou A, Barrau K et al (2007) Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 56:621–623PubMedCrossRefGoogle Scholar
  116. 116.
    Young L, Czarnecki D (2012) The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis. Australas J Dermatol 53:57–60PubMedCrossRefGoogle Scholar
  117. 117.
    Yu CC, Cook MG (1990) Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol 122:763–769PubMedCrossRefGoogle Scholar
  118. 118.
    Zarchi K, Dufour DN, Jemec GBE (2013) Successful treatment of severe hidradenitis suppurativa with anakinra. JAMA Dermatol 149:1192–1194PubMedCrossRefGoogle Scholar
  119. 119.
    Zitelli KB, Zedek D, Ranganathan P et al (2013) Squamous cell carcinoma of the lip associated with adalimumab therapy for ankylosing spondylitis: a case report and review of TNF-alpha inhibitors and cutaneous carcinoma risk. Cutis 92:35–39PubMedGoogle Scholar
  120. 120.
    Zouboulis CC, Bechara FG, Fritz K et al (2012) S1– Leitlinie zur Therapie der Hidradenitis suppurativa/Acne inversa. J Dtsch Dermatol Ges 10(Suppl 5):S1–S31CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Klinik für Dermatologie, Venerologie und AllergologieHELIOS St. Elisabeth Klinik OberhausenOberhausenDeutschland
  2. 2.Klinik für Dermatologie, Venerologie und Allergologie, Abteilung für DermatochirurgieSt. Josef-Hospital, Klinik der Ruhr-Universität BochumBochumDeutschland

Personalised recommendations